Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase

ConclusionsA pre-infusion sUA level functions as a highly accurate biomarker for identification of patients who are at risk of IRs while on pegloticase therapy. Stopping pegloticase in patients who have a rise in pre-infusion uric acid levels to above 6  mg/dl while on therapy would result in most IRs being avoided.FundingHorizon Pharma.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research